Skip Navigation

Urologic Surgery Trials

For enrollment information involving the following trials, please contact one of the research staff members on the "Meet the Team" page.

Endoscopic Visualization & Outcomes (WATER vs. SALINE)

Perioperative Physical Activity (PEDOMETER)

Frailty Study

Tissue Bank

ENDOSCOPIC VISUALIZATION & OUTCOMES (WATER vs. SALINE)

The effects of water versus saline on absorption rates and visualization during ureteroscopy.

Eligibility:

• Adult patients meeting medical requirements to undergo ureteroscopy (diagnostic and/or treatment)
• Patient must be consentable or have a legal representative sign the ICF

Exclusion Criteria:

• None

Treatment:

The purpose of this study is to determine if the use of water or saline during ureteroscopy—a procedure where a small ureteroscope is used to guide through the ureter and renal (kidney) collecting system—has any clinical implications such as improved visualization, decreased operative time, and improved patient outcomes.

Principal Investigators: Dr. Kenneth Ogan, Dr. John Pattaras

PERIOPERATIVE PHYSICAL ACTIVITY (PEDOMETER)

Prospective randomized study of exercise in patients undergoing urologic surgery.

Eligibility:

• Adult patients scheduled for operative procedure with an inpatient postoperative stay
• Willing and able to give blood samples, complete a questionnaire, and fill out the step log

Exclusion Criteria:

• None

Treatment:

Patients are given a pedometer and asked to record their daily steps in a log. The purpose of this study is to determine if we are able to increase patients’ physical activity in the perioperative period with the aide of pedometers.

Principal Investigators: Dr. Kenneth Ogan, Dr. Viraj Master, Dr. John Pattaras, Dr. Peter Nieh

FRAILTY STUDY

This study investigates frailty as a predictor of outcomes in patients undergoing major surgical procedures. The purpose of this study is to understand and qualify the impact of frailty as a pre-operative risk criteria. This information would assist both surgeons and patients in optimizing management decisions in the future.

Eligibility:

• Patients scheduled to undergo major surgical procedures (urologic, colorectal, intra-abdominal and/or vascular)
• Patients willing to do the study preoperative assessment tools

Exclusion Criteria:

• Cognitive disorders (dementia, CVA, etc.)
• Neurologic disorder with functional motor disorder (Parkinson's disease, multiple sclerosis, stroke, etc.)
• Depression treated with antidepressant medications
• Patients taking Carbidopa, Levodoa or Donepezil

Principal InvestigatorS: Dr. Kenneth Ogan, Dr. Viraj Master

Co-Investigators & Collaborators: Dr. John Pattaras, Dr. Peter Nieh, and four surgeons from the Department of Surgery: Dr. John Sweeney, Dr. David Kooby, Dr. Shishir Maithel, Dr. Shipra Arya

TISSUE BANK

Urological tissue and specimen bank at Emory University and affiliated medical centers.

Eligibility:

The study is open to all male and female patients undergoing evaluation for surgical treatment/removal of urologic organs and tissue. This includes:

• Men: kidneys, bladder, prostate, seminal vesicles, and lymph nodes
• Women: kidneys, bladder, uterus, ovaries, vaginal tissue, fallopian tubes and lymph nodes

Eligible Treatment Centers:

• Emory University Hospital
• The Emory Clinic
• Emory Saint Joseph's Hospital
• Emory Midtown Hospital
• Grady Memorial Hospital

Exclusion Criteria

• None

Other Information:

• Following surgical removal of the urologic organ, all tissue will be processed by the pathology department for routine standard histopathological examination. For the specimen bank, a small portion of the tissue will be used for research testing.
• Additional specimens such as blood, urine, and saliva may be collected for research purposes.
• Patient medical records and test results will be reviewed and compiled in a relational database for research analysis.

Principal Investigator: Dr. John Petros

Co-Investigators & Collaborators: Dr. Martin Sanda, Dr. Viraj Master, Dr. Adeboye Osunkoya (Department of Pathology and Laboratory Medicine), Dr. Joseph Shelton (Department of Radiation Oncology)

««return to top